Literature DB >> 19806474

Ventilator-associated pneumonia in a neurologic intensive care unit does not lead to increased mortality.

S Andrew Josephson1, Asma M Moheet, Michael A Gropper, Amy D Nichols, Wade S Smith.   

Abstract

BACKGROUND: Ventilator-associated pneumonia (VAP) is the most common nosocomial infection among medical intensive care unit (ICU) patients and is associated with increased mortality and length of stay (LOS). Neurologic disease is a risk factor for VAP development, but the relationship between VAP and outcomes in patients admitted to the ICU for neurologic reasons remains largely unknown.
METHODS: All mechanically ventilated patients over a 2-year period with neurovascular disease were included in a retrospective study. Data collected included patient demographics, dates of admission and discharge, LOS, and ventilator hours. Comparisons between neurologic patients who did and did not develop VAP were made using univariate and multivariate analysis.
RESULTS: Of 585 intubated neurovascular patients, 24 (4.1%) developed VAP. Compared with those who did not develop VAP, those with VAP were younger (51.8 +/- 13.9 years vs. 58.8 +/- 15.9 years, P = 0.03), had increased LOS (32.6 +/- 29.2 days vs. 14.5 +/- 7.8 days, P < 0.001), and more ventilator hours (272 +/- 257 h vs. 85.9 +/- 140 h, P < 0.001). There was no difference in mortality between patients with and without VAP (25.0% vs. 28.3%, P = 0.72). VAP was not an independent predictor of mortality in a multivariate model (OR 1.11, 95% CI 0.37-3.30, P = 0.855).
CONCLUSIONS: VAP in neurocritical care patients is associated with increased LOS and ventilator hours, but is not associated with increased mortality, contrary to prior studies in medical ICU patients.

Entities:  

Mesh:

Year:  2010        PMID: 19806474     DOI: 10.1007/s12028-009-9285-x

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  15 in total

Review 1.  Ventilator associated pneumonia: perspectives on the burden of illness.

Authors:  D Cook
Journal:  Intensive Care Med       Date:  2000       Impact factor: 17.440

2.  Nonpayment for performance? Medicare's new reimbursement rule.

Authors:  Meredith B Rosenthal
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

Review 3.  Neurohospitalists: an emerging model for inpatient neurological care.

Authors:  S Andrew Josephson; John W Engstrom; Robert M Wachter
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

4.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

5.  Strategies to prevent ventilator-associated pneumonia in acute care hospitals.

Authors:  Susan E Coffin; Michael Klompas; David Classen; Kathleen M Arias; Kelly Podgorny; Deverick J Anderson; Helen Burstin; David P Calfee; Erik R Dubberke; Victoria Fraser; Dale N Gerding; Frances A Griffin; Peter Gross; Keith S Kaye; Evelyn Lo; Jonas Marschall; Leonard A Mermel; Lindsay Nicolle; David A Pegues; Trish M Perl; Sanjay Saint; Cassandra D Salgado; Robert A Weinstein; Robert Wise; Deborah S Yokoe
Journal:  Infect Control Hosp Epidemiol       Date:  2008-10       Impact factor: 3.254

6.  Early gastrostomy reduces the rate of ventilator-associated pneumonia in stroke or head injury patients.

Authors:  E Kostadima; A G Kaditis; E I Alexopoulos; E Zakynthinos; D Sfyras
Journal:  Eur Respir J       Date:  2005-07       Impact factor: 16.671

7.  Intrahospital transport of critically ill ventilated patients: a risk factor for ventilator-associated pneumonia--a matched cohort study.

Authors:  Nicolas Bercault; Manuel Wolf; Isabelle Runge; Jean-Christian Fleury; Thierry Boulain
Journal:  Crit Care Med       Date:  2005-11       Impact factor: 7.598

Review 8.  Clinical and economic consequences of ventilator-associated pneumonia: a systematic review.

Authors:  Nasia Safdar; Cameron Dezfulian; Harold R Collard; Sanjay Saint
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

9.  Prone position as prevention of lung injury in comatose patients: a prospective, randomized, controlled study.

Authors:  Pascal Beuret; Marie-Jose Carton; Karim Nourdine; Mahmoud Kaaki; Gerard Tramoni; Jean-Claude Ducreux
Journal:  Intensive Care Med       Date:  2002-04-09       Impact factor: 17.440

10.  Oral care intervention to reduce incidence of ventilator-associated pneumonia in the neurologic intensive care unit.

Authors:  Lorraine B Fields
Journal:  J Neurosci Nurs       Date:  2008-10       Impact factor: 1.230

View more
  5 in total

1.  The Severity of ICU-Acquired Pneumonia.

Authors:  Hugues Marechal; Nathalie Layios; Pierre Damas
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

2.  Ventilators in ICU: A boon or burden.

Authors:  Man Mohan Mehndiratta; Rajeev Nayak; Sana Ali; Ajay Sharma; Natasha Singh Gulati
Journal:  Ann Indian Acad Neurol       Date:  2016 Jan-Mar       Impact factor: 1.383

3.  Low incidence of multidrug-resistant bacteria and nosocomial infection due to a preventive multimodal nosocomial infection control: a 10-year single centre prospective cohort study in neurocritical care.

Authors:  Vera Spatenkova; Ondrej Bradac; Daniela Fackova; Zdenka Bohunova; Petr Suchomel
Journal:  BMC Neurol       Date:  2018-03-07       Impact factor: 2.474

Review 4.  Incidence, Risk Factors, and Outcomes of Ventilator-Associated Pneumonia in Traumatic Brain Injury: A Meta-analysis.

Authors:  Yating Li; Chenxia Liu; Wei Xiao; Tiantian Song; Shuhui Wang
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

5.  Microbiology and Outcomes of Institutionalized Patients With Stroke-Associated Pneumonia: An Observational Cohort Study.

Authors:  Jie Zhao; Lei-Qing Li; Ning-Xin Zhen; Lin-Lin Du; Hui Shan; Yang Yu; Zhao-Cai Zhang; Wei Cui; Bao-Ping Tian
Journal:  Front Microbiol       Date:  2021-12-03       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.